Targeting human satellite II (HSATII)

US10301624B2 · kind B2 · utility

Assignees

• The General Hospital Corporation · US
• Aalborg Universitet · DK

Inventors

• David T. Ting · Dover, US
• Daniel A. Haber · Sharon, US
• Shyamala Maheswaran · Lexington, US
• Francesca Bersani · Torino, IT
• Anders M. Naar · Arlington, US
• Mihir Shivadatta Rajurkar · Worcester, US
• Sakari Kauppinen · Haslev, DK
• Andreas Petri · Copenhagen, DK

Key dates

• Filing date: Jun 25, 2015
• Grant date: May 28, 2019
• Expiry date: Jun 25, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.